FDA Approves Generic Version of Sinemet for Parkinson’s Treatment, Company Says
The U.S. Food and Drug Administration (FDA) has approved a generic equivalent to Sinemet (carbidopa/levodopa) for the…
Articles by Patricia Inácio, PhD
Distinct Brain Activity Patterns Captured by EEG May Help in Treating Parkinson’s, Study Suggests
Measuring the electric brain activity of people with Parkinson’s may be a non-invasive and accurate way of diagnosing the disease…
Lysosome-targeting Therapies Can Potentially Reverse LRRK2 Effects in Parkinson’s, Study Suggests
Mutations in the LRRK2 gene, which have been linked to familial Parkinson’s disease, impair the activity of the…
Mindfulness Exercises Lessen Stress, Anxiety Symptoms Among Caregivers of Veterans, Study Shows
Mindfulness-based interventions can improve mental health status, including reduction of stress and anxiety levels, in family caregivers of veterans with…
#AANAM — Investigational VY-AADC01 Gene Therapy Provides Benefits for Parkinson’s Patients, Phase 1 Data Show
A single-dose infusion of VY-AADC01, an investigational gene therapy, improves motor function and reduces the need for antiparkinsonian medications in…
Studying Epigenetic Changes May Help Diagnose Parkinson’s Disease Earlier, Researchers Say
Understanding and identifying epigenetic changes may become a potential strategy for early Parkinson’s diagnosis, when patients still lack the characteristic symptoms…
Pilot Project Tests Wrist Device That Monitors Symptoms at Home
A pilot project in the United Kingdom is testing a wrist device that is worn like a watch, called Personal…
Researchers Receive $1 Million to Identify New Genes Involved in PD
A project to identify new genes involved in the development of Parkinson’s disease has received $1 million in funding from…
Phase 1/2 Trial to Test Investigational Therapy RTB101 in Parkinson’s Disease
A new Phase 1/2a clinical trial will investigate resTORbio’s therapy candidate RTB101, alone or in combination with sirolimus,…
ProMIS to Present Data on Potential of Antibodies to Target Toxic Alpha-Synuclein in Parkinson’s
ProMIS Neurosciences will present evidence of the selectivity of several of its antibody candidates to target the toxic forms of…